JP2023088996A5 - - Google Patents
Info
- Publication number
- JP2023088996A5 JP2023088996A5 JP2023045826A JP2023045826A JP2023088996A5 JP 2023088996 A5 JP2023088996 A5 JP 2023088996A5 JP 2023045826 A JP2023045826 A JP 2023045826A JP 2023045826 A JP2023045826 A JP 2023045826A JP 2023088996 A5 JP2023088996 A5 JP 2023088996A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- day
- tsa
- aurka
- effective dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869039P | 2013-08-22 | 2013-08-22 | |
| US61/869,039 | 2013-08-22 | ||
| JP2019088425A JP2019167351A (ja) | 2013-08-22 | 2019-05-08 | 癌治療 |
| JP2021042699A JP2021105005A (ja) | 2013-08-22 | 2021-03-16 | 癌治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021042699A Division JP2021105005A (ja) | 2013-08-22 | 2021-03-16 | 癌治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023088996A JP2023088996A (ja) | 2023-06-27 |
| JP2023088996A5 true JP2023088996A5 (enExample) | 2026-04-30 |
Family
ID=51794948
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536469A Pending JP2016528297A (ja) | 2013-08-22 | 2014-08-22 | 癌治療 |
| JP2019088425A Pending JP2019167351A (ja) | 2013-08-22 | 2019-05-08 | 癌治療 |
| JP2021042699A Pending JP2021105005A (ja) | 2013-08-22 | 2021-03-16 | 癌治療 |
| JP2023045826A Pending JP2023088996A (ja) | 2013-08-22 | 2023-03-22 | 癌治療 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536469A Pending JP2016528297A (ja) | 2013-08-22 | 2014-08-22 | 癌治療 |
| JP2019088425A Pending JP2019167351A (ja) | 2013-08-22 | 2019-05-08 | 癌治療 |
| JP2021042699A Pending JP2021105005A (ja) | 2013-08-22 | 2021-03-16 | 癌治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20160199323A1 (enExample) |
| EP (2) | EP3036007B1 (enExample) |
| JP (4) | JP2016528297A (enExample) |
| KR (5) | KR102315528B1 (enExample) |
| CN (2) | CN110585184A (enExample) |
| AU (4) | AU2014308700A1 (enExample) |
| CA (1) | CA2921036A1 (enExample) |
| CL (1) | CL2016000397A1 (enExample) |
| EA (1) | EA037667B1 (enExample) |
| ES (1) | ES2755983T3 (enExample) |
| MX (1) | MX381429B (enExample) |
| WO (1) | WO2015027121A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037638B1 (ru) * | 2013-08-22 | 2021-04-23 | Ванда Фармасьютикалз Инк. | Лечение множественной миеломы |
| KR102315528B1 (ko) * | 2013-08-22 | 2021-10-21 | 반다 파마슈티칼즈, 인코퍼레이티드. | 암 치료 |
| WO2021016203A1 (en) * | 2019-07-19 | 2021-01-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target |
| US20250161242A1 (en) * | 2022-03-01 | 2025-05-22 | Vanda Pharmaceuticals Inc. | Trichostatin a (tsa) sensitivity in the treatment of tumors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4218478A (en) * | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
| CA1265431A (en) | 1985-01-08 | 1990-02-06 | Roderick John Macdonald | Electrode device for flare stack ignitor |
| JPS61176523A (ja) | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| WO2002060430A1 (en) * | 2001-02-01 | 2002-08-08 | Cornell Research Foundation, Inc. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
| DK2238982T3 (da) * | 2003-06-27 | 2013-01-28 | Astellas Pharma Inc | Terapeutisk middel til blødt væv-sarcom |
| DK2537942T3 (en) | 2004-05-21 | 2015-12-14 | Trustees Of The University Of Arkansas System Board Of | Use of genudtryksprofilering to predict survival in cancer patients |
| GB0519405D0 (en) | 2005-09-23 | 2005-11-02 | Univ Aberdeen | Cancer therapy prognosis and target |
| WO2007067516A2 (en) * | 2005-12-06 | 2007-06-14 | Duke University | Multiple myeloma |
| CA2652888A1 (en) | 2006-05-26 | 2007-12-06 | Celgene Corporation | Methods and compositions using immunomodulatory compounds in combination therapy |
| CA2574531C (en) * | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| EP2356255A2 (en) | 2008-12-05 | 2011-08-17 | The Institute of Cancer Research : The Royal Cancer Hospital | Methods for determining a prognosis in multiple myeloma |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| US9670549B2 (en) * | 2011-11-10 | 2017-06-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene expression signatures of neoplasm responsiveness to therapy |
| EP2602330A1 (en) | 2011-12-07 | 2013-06-12 | Palacky University, Olomouc | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance |
| WO2013184572A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| EA037638B1 (ru) | 2013-08-22 | 2021-04-23 | Ванда Фармасьютикалз Инк. | Лечение множественной миеломы |
| KR102315528B1 (ko) * | 2013-08-22 | 2021-10-21 | 반다 파마슈티칼즈, 인코퍼레이티드. | 암 치료 |
| DE102014117278A1 (de) | 2014-11-25 | 2016-05-25 | Krones Ag | Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage |
-
2014
- 2014-08-22 KR KR1020217002758A patent/KR102315528B1/ko active Active
- 2014-08-22 EP EP14789436.4A patent/EP3036007B1/en active Active
- 2014-08-22 CA CA2921036A patent/CA2921036A1/en active Pending
- 2014-08-22 KR KR1020237010047A patent/KR20230047203A/ko not_active Abandoned
- 2014-08-22 JP JP2016536469A patent/JP2016528297A/ja active Pending
- 2014-08-22 MX MX2016002307A patent/MX381429B/es unknown
- 2014-08-22 CN CN201910836673.3A patent/CN110585184A/zh active Pending
- 2014-08-22 WO PCT/US2014/052209 patent/WO2015027121A2/en not_active Ceased
- 2014-08-22 CN CN201480046624.5A patent/CN105579101A/zh active Pending
- 2014-08-22 KR KR1020177032020A patent/KR20170126018A/ko not_active Ceased
- 2014-08-22 AU AU2014308700A patent/AU2014308700A1/en not_active Abandoned
- 2014-08-22 EP EP19201777.0A patent/EP3616754A1/en active Pending
- 2014-08-22 KR KR1020217033186A patent/KR20210127821A/ko not_active Ceased
- 2014-08-22 ES ES14789436T patent/ES2755983T3/es active Active
- 2014-08-22 KR KR1020167004630A patent/KR20160033779A/ko not_active Ceased
- 2014-08-22 EA EA201690445A patent/EA037667B1/ru unknown
- 2014-08-22 US US14/912,077 patent/US20160199323A1/en not_active Abandoned
-
2016
- 2016-02-22 CL CL2016000397A patent/CL2016000397A1/es unknown
-
2018
- 2018-05-15 US US15/980,644 patent/US10265282B2/en active Active
-
2019
- 2019-03-18 US US16/357,249 patent/US11078289B2/en active Active
- 2019-05-08 JP JP2019088425A patent/JP2019167351A/ja active Pending
- 2019-11-06 AU AU2019261718A patent/AU2019261718A1/en not_active Abandoned
-
2021
- 2021-03-16 JP JP2021042699A patent/JP2021105005A/ja active Pending
- 2021-06-28 US US17/359,986 patent/US11667718B2/en active Active
- 2021-11-03 AU AU2021261882A patent/AU2021261882B2/en active Active
-
2022
- 2022-03-30 AU AU2022202183A patent/AU2022202183B2/en active Active
-
2023
- 2023-03-22 JP JP2023045826A patent/JP2023088996A/ja active Pending
- 2023-04-25 US US18/306,601 patent/US12590162B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021105005A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP5973684B2 (ja) | 癌治療のための使用 | |
| HRP20120802T1 (hr) | Derivati piperidina i piperazina za lijeäśenje tumora | |
| HK1199710A1 (en) | Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers | |
| WO2015188169A1 (en) | Novel sesquiterpene derivatives and their use in inflammation and cancer treatment | |
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| CN101600426B (zh) | 用于治疗肠道疾病的异山梨醇单硝酸酯衍生物 | |
| JP2023088996A (ja) | 癌治療 | |
| Gershanovich et al. | Results of clinical study of antitumor action of hydrazine sulfate | |
| CN102475710B (zh) | 薯蓣皂苷元及其衍生物在制备肿瘤化疗增敏药物中的应用 | |
| Xu et al. | Berberine inhibits the growth of osteosarcoma through modulating MMP/NM-23 and MAPK/JNK signal pathways | |
| JP2013544892A5 (enExample) | ||
| PH12021552973A1 (en) | Methods of treating urinary system cancers | |
| WO2014153023A1 (en) | 5-bromo-indirubins | |
| JP2024541900A5 (enExample) | ||
| CN108191860B (zh) | 一种HIF-2α小分子抑制剂及其用途 | |
| CA2878987C (en) | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma | |
| CN109010333A (zh) | 脱氢弯孢霉素在抑制Hedgehog通路中的应用 | |
| WO2014157443A1 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| TWI848990B (zh) | 治療化療難治性癌症的新聯合用藥方案 | |
| WO2006106984A1 (ja) | ピリジン誘導体を有効成分とする放射線治療増強剤 | |
| JP2019503370A (ja) | ベニバナボロギク抽出物を調製する方法、それにより調製された抽出物、及び抽出物の使用 | |
| CN107445931A (zh) | 土木香内酯衍生物，其药物组合物及其制备方法和用途 | |
| Patwardhan et al. | Antioxidant flavonoid baicalein as a dual purpose radiomodifier with promising bench to bedside potential |